Related Experiment Video
Updated: Feb 11, 2026

Formation of Dispersible Taohong Siwu Tablets
Published on: February 3, 2023
Pharmacologic and clinical comparison of cefaclor in immediate-release capsule and extended-release tablet forms
1Imperial College School of Medicine, Royal Brampton National Heart & Lung Institute, London, UK.
Abstract:
A new controlled-delivery, extended-release 500-mg formulation of cefaclor that is administered twice daily may improve patient compliance compared with the older, immediate-release 250-mg formulation that is administered three times daily. When the extended-release tablet is administered with food, peak plasma cefaclor concentrations are achieved about 2.5 hours after the dose compared with about 1 hour after a dose with the immediate-release capsule. However, the two formulations have an equivalent extent of absorption and equivalent pharmacokinetics after absorption. Cefaclor has retained its excellent in vitro activity against the pathogens most commonly associated with acute exacerbations of chronic bronchitis, namely, Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae. Clinical trials show similar efficacy of the two formulations in patients with acute exacerbations of chronic bronchitis caused by these organisms, but for this indication a 7-day regimen may be used with the extended-release 500-mg formulation compared with a 10-day dosing regimen with the 250-mg capsule. The shorter course of treatment with the new formulation may also improve patient compliance.
More Related Videos
07:56A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
Published on: August 11, 2021
07:07Controlled-release of Chlorine Dioxide in a Perforated Packaging System to Extend the Storage Life and Improve the Safety of Grape Tomatoes
Published on: April 7, 2017
Related Concept Videos
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
In Vitro Drug Release Testing: Overview, Development and Validation
Energy-releasing Steps of Glycolysis
The first energy-releasing step—the 6th step of glycolysis...
ATP Energy Storage and Release
One example of energy coupling using ATP involves a...
Drugs Affecting Neurotransmitter Release or Uptake
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...